"Nuclear medicines, like radioligand therapy, could be transformative for cancer care in Australia. Establishing clear pathways for market access and a thriving nuclear medicine industry will be key to enabling Australian patients to access these new treatment options," said Novartis country president Matt Zeller.
New Novartis-backed report identifies nuclear medicine opportunity but calls for change
April 19, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Company size shapes CEO pay trends in Australian health care and biotechnology
October 6, 2026 - - Latest News -
Young NZ cancer patients to get funded medicines no matter where they are treated
October 6, 2026 - - Latest News -
TGA turns to national security surveillance platform to police therapeutic goods compliance
October 6, 2026 - - Latest News -
CSL announces investment for share of Alentis rare kidney and liver candidate
October 6, 2026 - - Latest News -
TGA approves Roche's refillable eye implant for wet macular degeneration
October 5, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.34
October 2, 2026 - - Podcast -
Under the TGA's new rules, the safest story is one without the patient experience
October 2, 2026 - - Latest News
